Caricamento...
Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human' dose for stroke studies in rats?
Since a pioneer work that has shown in vitro that the rat's fibrinolytic system is 10-fold less sensitive to recombinant tissue-plasminogen activator (rtPA) than the human system, most preclinical studies are performed with 10 instead of 0.9 mg/kg rtPA (the clinical dose in stroke patients). In...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2949192/ https://ncbi.nlm.nih.gov/pubmed/20216551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jcbfm.2010.33 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|